Le Lézard15d
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy
Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows ...
Le Lézard9d
TRX LAUNCHES NEW PHYSICAL THERAPY & REHABILITATION TOOLS & EDUCATION
Functional training leader TRX is advancing into the physical therapy & rehab sector via a three-pronged approach to injury recovery: PT-approved tools for clinic settings, PT-approved science-backed ...
GEN25d
Insilico, U. Toronto Researchers Develop Quantum-Classical Computing AI Model
“This training helped to optimize the hybrid ... owned AI drug discovery pipeline and has received the FDA’s orphan drug designation for the treatment of mesothelioma. Also in oncology ...
Medscape10d
Underfunded, Underdiagnosed, and Misunderstood: What’s Next for Bipolar Disorder
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
India Infoline7d
Zydus Lifesciences Ltd Summary
Zydus will set its own prices for the generic product, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other business ...
Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders
The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.
PharmaTimes29d
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...
PharmaTimes15d
FDA grants Orphan Drug Designation to Ariceum cancer therapy
has granted Orphan Drug Designation (ODD) to its proprietary radiopharmaceutical, 225Ac-satoreotide, for treating patients with Small Cell Lung Cancer (SCLC). SCLC is a severe condition with a poor ...
PharmiWeb7d
Orphan Drugs Market: A Comprehensive Analysis (2024-2035)
Additionally, regulatory designations such as the Orphan Drug Designation (ODD) provide exclusivity periods, allowing companies to benefit from market monopolies for extended durations. This ...
PharmiWeb14d
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
225 Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows ...
Yahoo Finance4d
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Biodexa, which has already received U.S. FDA Orphan Drug designation for eRapa in FAP, plans to seek a similar designation in Europe. eRapa is a proprietary oral tablet formulation of rapamycin ...
Business Wire29d
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).